NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
AstraZeneca
Bristol-Myers Squibb
Bristol-Myers Squibb
Merus B.V.
Shenzhen Hornetcorn Bio-technology Company, LTD
Binex